Alzheimer's disease Archimedes condition‐event simulator: Development and validation

Alzheimer's and Dementia: Translational Research and Clinical Interventions - Tập 4 - Trang 76-88 - 2018
Anuraag R. Kansal1, Ali Tafazzoli1, K. Jack Ishak2, Stanmira Krotneva2
1Modeling and Simulation, Evidera, Bethesda, MD, USA
2Modeling and Simulation, Evidera, St-Laurent, Quebec, Canada

Tóm tắt

AbstractIntroductionSeveral advances have been made in Alzheimer's Disease (AD) modeling, however, there remains a need for a simulator that represents the full scope of disease progression and can be used to study new disease‐modifying treatments for early‐stage and even prodromal AD.MethodsWe developed AD Archimedes condition‐event simulator, a patient‐level simulator with a focus on simulating the effects of early interventions through changes in biomarkers of AD. The simulator incorporates interconnected predictive equations derived from longitudinal data sets.ResultsThe results of external validations on AD Archimedes condition‐event simulator showed that it provides reasonable estimates once compared to literature results on transition to dementia AD, institutionalization, and mortality. A case study comparing a disease‐modifying treatment and a symptomatic treatment also showcases the benefits of early treatment.DiscussionThe AD Archimedes condition‐event simulator is designed to perform economic evaluation on various interventions through close tracking of disease progression and the related clinical outcomes.

Tài liệu tham khảo

10.1016/j.jalz.2008.02.003 10.2165/00019053-200725090-00003 10.1016/j.jval.2010.12.008 Loveman E., 2006, The clinical and cost‐effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease, Health Technol Assess, 10, 10.3310/hta10010 10.1586/14737167.8.3.273 10.2165/11631830-000000000-00000 10.3310/hta16210 10.1212/WNL.57.6.964 10.2165/11531870-000000000-00000 10.1016/j.jalz.2016.12.005 10.1007/s40273-016-0392-1 10.1016/j.jval.2012.06.012 10.1212/WNL.55.4.484 10.1007/s40273-016-0394-z Alzheimer's Disease Neuroimaging Initiative (ADNI). ADNI Dataset 2015. Alzheimer's Disease Neuroimaging Initiative; 2014. McCulloch C.E., 2001, Generalized linear mixed models 10.1007/s40273-014-0203-5 10.1097/01.JGP.0000192478.82189.a8 O’Bryant S.E., 2010, Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the National Alzheimer's Coordinating Center database, Arch Neurol, 67, 746, 10.1001/archneurol.2010.115 10.3111/13696998.2010.528101 10.1212/WNL.57.6.957 10.1001/archneurol.2009.80 Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS), National Vital Statistics System, 2006, Worktable 210F. Deaths from 113 selected causes, alcohol‐induced causes, drug‐induced causes, and injury by firearms, by 5‐year age groups, race and sex: United States Social Security Administration. Social Security Actuarial Life Table. Period Life Table 2011. Social Security Administration; 2014. Available at:https://www.ssa.gov/oact/STATS/table4c6.html. 10.1177/0272989X06290495 10.1177/0272989X0002000405 10.1016/j.jalz.2010.09.001 10.1007/s00415-010-5650-0 10.1037/a0029857 Razlighi Q.R., 2014, A new algorithm for predicting time to disease endpoints in Alzheimer's disease patients, J Alzheimers Dis, 38, 661, 10.3233/JAD-131142 10.1159/000335364
Thông tin
Thông tin xuất bản

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Tập 4

76-88

Thông tin tác giả